These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27115107)

  • 1. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
    Reis J; Aguiar F; Brito I
    Acta Reumatol Port; 2016; 41(1):45-55. PubMed ID: 27115107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab use in young adults diagnosed with juvenile idiopathic arthritis unresponsive to conventional treatment: report of 6 cases.
    Sakamoto AP; Pinheiro MM; Barbosa CM; Fraga MM; Len CA; Terreri MT
    Rev Bras Reumatol; 2015; 55(6):536-41. PubMed ID: 26066294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.
    Kearsley-Fleet L; Sampath S; McCann LJ; Baildam E; Beresford MW; Davies R; De Cock D; Foster HE; Southwood TR; Thomson W; Hyrich KL
    Rheumatology (Oxford); 2019 Feb; 58(2):331-335. PubMed ID: 30358861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.
    Tambralli A; Beukelman T; Cron RQ; Stoll ML
    J Rheumatol; 2015 Mar; 42(3):541-6. PubMed ID: 25593242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.
    Olfat M; Silverman ED; Levy DM
    Lupus; 2015 Aug; 24(9):966-72. PubMed ID: 25804672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.
    Trachana M; Koutsonikoli A; Farmaki E; Printza N; Tzimouli V; Papachristou F
    Rheumatol Int; 2013 Mar; 33(3):809-13. PubMed ID: 22101555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
    Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
    Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of bone mass and quality determinants in adolescents and young adults with juvenile systemic lupus erythematosus (JSLE) and juvenile idiopathic arthritis (JIA).
    Stagi S; Cavalli L; Bertini F; Signorini C; Matucci Cerinic M; de Martino M; Brandi ML; Falcini F
    Lupus; 2014 Nov; 23(13):1392-406. PubMed ID: 25074873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept treatment for children with refractory juvenile idiopathic arthritis.
    Kuo HC; Yu HR; Wu CC; Chang LS; Yang KD
    J Microbiol Immunol Infect; 2011 Feb; 44(1):52-6. PubMed ID: 21531353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
    Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
    Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric systemic lupus erythematosus in Thammasat University Hospital.
    Pusongchai T; Jungthirapanich J; Khositseth S
    J Med Assoc Thai; 2010 Dec; 93 Suppl 7():S283-93. PubMed ID: 21294427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort.
    Sawhney S; Agarwal M
    Lupus; 2021 Oct; 30(11):1829-1836. PubMed ID: 34315295
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.
    Iaccarino L; Bartoloni E; Carli L; Ceccarelli F; Conti F; De Vita S; Ferraccioli G; Galeazzi M; Gatto M; Gerli R; Govoni M; Gremese E; Iuliano A; Mansutti E; Moroni G; Mosca M; Nalli C; Naretto C; Padovan M; Palma L; Raffiotta F; Roccatello D; Tincani A; Valesini G; Zen M; Doria A
    Clin Exp Rheumatol; 2015; 33(4):449-56. PubMed ID: 26053285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of paediatric rheumatic disorders at a tertiary hospital in Tanzania.
    Furia FF; Godfrey E; Mwamanenge N; Swai P
    Pediatr Rheumatol Online J; 2020 Apr; 18(1):30. PubMed ID: 32245494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The retrospective evaluation of efficacy and safety data after switching from originator rituximab to biosimilar rituximab (CT-P10) in patients diagnosed with systemic lupus erythematosus: a single-center experience.
    Ekin A; Mısırcı S; Coşkun BN; Yağız B; Dalkılıç E; Pehlivan Y
    Eur Rev Med Pharmacol Sci; 2024 May; 28(10):3513-3522. PubMed ID: 38856126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years.
    Aguiar R; Araújo C; Martins-Coelho G; Isenberg D
    Arthritis Care Res (Hoboken); 2017 Feb; 69(2):257-262. PubMed ID: 27110698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
    Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
    Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
    Jiang B; Li T; Guo L; Shen H; Ye S; Chen S
    J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.